Form 8-K - Current report:
SEC Accession No. 0001193125-25-115482
Filing Date
2025-05-08
Accepted
2025-05-08 07:31:50
Documents
16
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d938501d8k.htm   iXBRL 8-K 25828
2 EX-99.1 d938501dex991.htm EX-99.1 161259
6 GRAPHIC g938501g0505225924496.jpg GRAPHIC 6420
7 GRAPHIC g938501g0505225924819.jpg GRAPHIC 1424
  Complete submission text file 0001193125-25-115482.txt   339854

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20250508.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20250508_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20250508_pre.xml EX-101.PRE 10815
19 EXTRACTED XBRL INSTANCE DOCUMENT d938501d8k_htm.xml XML 3727
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 25923898
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)